LYBALVI®
(olanzapine and samidorphan)
Publications
Studies designed, executed, and funded by Alkermes Inc.
Mar 2019
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia
American Journal of Psychiatry
AUTHOR(S)
Mar 2020
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study
The Journal of Clinical Psychiatry
AUTHOR(S)
Dec 2020
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study
The American Journal of Psychiatry
AUTHOR(S)
Jun 2021
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
Schizophrenia Research
AUTHOR(S)
Aug 2021
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
CNS Spectrums
AUTHOR(S)
Aug 2021
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
Neuropsychiatric Disease and Treatment
AUTHOR(S)
Mar 2023
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
Schizophrenia Bulletin
AUTHOR(S)
Mar 2023
Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study
The Journal of Clinical Psychiatry
AUTHOR(S)
Dec 2024
Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
The Journal of Clinical Psychiatry
AUTHOR(S)
